GSK announced the start of a phase III study investigating Benlysta (belimumab) in combination with rituximab in adult patients with...
Read more
Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body...
Read more
UrgoStart® heals 60% more patients compared to a well-managed standard treatment, and reduces healing time by 60 days (compared to...
Read more
Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved...
Read more
A research team from Tongji University in China have made a breakthrough in human lung regeneration technology. For the first...
Read more
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and...
Read more
SMM evaluated the efficacy and safety of POMALYST/IMNOVID (pomalidomide) plus bortezomib and low-dose dexamethasone (PVd) versus bortezomib and low-dose dexamethasone...
Read more
Roche announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment...
Read more
Shire plc the global biotechnology leader in rare diseases, today announced that it will have 12 presentations, including 11 posters...
Read more
Celgene Corporation announced that the Phase III, randomized, open-label, international clinical study, OPTIMISMM, achieved its primary endpoint, showing a statistically...
Read more
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
